However, a reasonably successful but costly therapeutic target in IBD is the use of TNFα inhibitors, including Infliximab and similar agents, to reduce the effect of the TNFα mediated pro-inflammatory cascade associated with chronic inflammation. The gene discussed is TNF; the disease is inflammatory bowel disease.